Literature DB >> 13489497

Long-term management of patients after adrenalectomy.

B SIMKIN.   

Abstract

Experience with the long-term medical management of 17 patients previously subjected to surgical adrenalectomy was reviewed. Maintenance adrenal cortical replacement requirements consisted of oral cortisone, 37.5 to 50 mg. daily in all patients; desoxycorticosterone acetate (DOCA), 2 mg. daily, sublingually in all patients; and supplemental sodium chloride, 1 to 4 grams daily, in seven patients. This provides steroids with glucocorticoid and mineralocorticoid activity and an adequate salt intake. The subjective well-being of the patient was the best indicator of adequate replacement therapy. Under stable conditions, established dosage schedules required surprisingly little adjustment over long periods of time. The primary need of patients without adrenal glands when they are subjected to such stresses as infections, trauma or surgical operation, is for more glucocorticoids. Ordinarily, more DOCA and extra sodium chloride is not required. Mild infections can be dealt with by temporarily increasing the daily oral cortisone requirement, the patient remaining ambulatory. Severe infections with pronounced systemic manifestations require hospitalization and parenteral administration of glucocorticoids. Knowing how long it takes for the various glucocorticoid preparations to take effect and how long they continue to act is important in the management of patients who have had adrenalectomy, particularly in dealing with extraordinary stresses or emergencies.

Entities:  

Keywords:  ADRENALECTOMY

Mesh:

Substances:

Year:  1957        PMID: 13489497      PMCID: PMC1512203     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  15 in total

1.  A water-soluble preparation of hydrocortisone for clinical use.

Authors:  R H ORR; V DI RAIMONDO; M E FLANAGAN; P H FORSHAM
Journal:  J Clin Endocrinol Metab       Date:  1955-06       Impact factor: 5.958

2.  Adrenalectomy for metastatic breast carcinoma.

Authors:  M GALANTE; D J FOURNIER; D A WOOD
Journal:  J Am Med Assoc       Date:  1957-03-23

3.  The use of intravenous hydrocortisone in major surgery.

Authors:  J M RUKES; R H ORR; P H FORSHAM; M GALANTE
Journal:  Ann N Y Acad Sci       Date:  1955-05-27       Impact factor: 5.691

4.  Comparison of the metabolic effects of cortisone and hydrocortisone in man.

Authors:  J C LAIDLAW; J R DINGMAN; W L ARONS; J T FINKENSTAEDT; G W THORN
Journal:  Ann N Y Acad Sci       Date:  1955-05-27       Impact factor: 5.691

5.  Cortical and medullary adrenal activity in surgical and allied conditions.

Authors:  C FRANKSSON; C A GEMZELL; U S VON EULER
Journal:  J Clin Endocrinol Metab       Date:  1954-06       Impact factor: 5.958

6.  Clinical and metabolic studies of bilateral adrenalectomy for advanced cancer in man.

Authors:  O H PEARSON; W F WHITMORE; C D WEST; J H FARROW
Journal:  Surgery       Date:  1953-09       Impact factor: 3.982

7.  Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast.

Authors:  C HUGGINS; T L Y DAO
Journal:  J Am Med Assoc       Date:  1953-04-18

8.  Clinical studies on the activity of orally administered cortisone.

Authors:  G W THORN; A E RENOLD; D L WILSON; T F FRAWLEY; D JENKINS; J GARCIA-REYES; P H FORSHAM
Journal:  N Engl J Med       Date:  1951-10-11       Impact factor: 91.245

9.  Bilateral adrenalectomy for advanced carcinoma of the breast with preliminary observations on the effect of the liver on the metabolism of adrenal cortical steroids.

Authors:  M GALANTE; J M RUKES; P H FORSHAM; D A WOOD; H G BELL
Journal:  Ann Surg       Date:  1954-10       Impact factor: 12.969

10.  Adrenalectomy for control of cancer of the breast.

Authors:  N FRIEDMAN; H L JAFFE; M H RABWIN; D H ROSENBLUM; B SIMKIN
Journal:  Calif Med       Date:  1956-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.